Skip to Content
Søk Menu
Vi dekker

ESMO I European Society for Medical Oncology

ESMO 2025

Sustained efficacy and quality of life with darolutamide + ADT in mHSPC patients of all ages

  • / Jan Andreasen

RNA Expression Profiles May Guide Future Targeted Therapy in Urothelial Cancer

/ Jan Andreasen
BlærekreftESMO25
Katharina Leuchte

ESMO 2025: High-Intensity Interval Training Promotes Immune Responses in mNSCLC Patients

/ Katharina Leuchte
ESMO25Lungekreft Play the Video

Combination Therapy with Enzalutamide and Radium-223 in mCRPC: Insights from the REASSURE Study

/ Igle Jan de Jong / Jan Andreasen
ESMO25
Load more

Artikler fra ESMO 2025

LBA20: Sacituzumab Govitecan Significantly Prolongs PFS versus Chemotherapy in Advanced Triple-Negative Breast Cancer

/ Jan Andreasen
BrystkreftESMO25NBCN

ESMO 2025: Darolutamide-Treated mHSPC Patients Show a More Durable and Stronger PSA Response vs Abiraterone 

/ Alicia Morgans / Jan Andreasen
ESMO25Prostatakreft

ESMO 2025: The Future of Oncology Will Be Built by Individuals

/ Jan Andreasen
ESMO25
Load more

Medtalks fra ESMO 2025

John Crown

ESMO 2025: Ribociclib + NSAI Reduced the Risk of Invasive and Distant Recurrence of HR+/HER2−Early Breast Cancer

/ John Crown
BrystkreftESMO25NBCN Play the Video
Charles Geyer

ESMO 2025: Paradigm Shift in Breast Cancer Treatment

/ Charles E Geyer Jr.
BrystkreftESMO25NBCN Play the Video
Jakob Lauritsen

ESMO 2025: Interesting New Data on the Treatment of Bladder Cancer

/ Jakob Lauritsen
BlærekreftESMO25 Play the Video
Load more

ESMO 2024

Hanna Dillekås

Ingen nye studier vil umiddelbart endre brystkreftbehandlingen i Norge, men flere har potensial på sikt

/ Hanna Dillekås
BrystkreftESMO24 Play the Video

ESMO Norsk Aften 2025

BestPractice Nordic og Medmeet er glade for å kunne invitere til Norsk Aften ESMO 2025 i Berlin. Møt kollegene dine og få en oppsummering av nyheter og høydepunkter fra kongressen – etterfulgt av nettverksbygging og middag.

Josep M Llovet

Perhaps a New Treatment Option for Patients with Intermediate Hepatocellular Carcinoma

/ Josep M. Llovet
ESMO24Leverkreft Play the Video

Oncology • Meet the experts

Få tilgang

Abstracts fra ESMO 2024

PD-1 Inhibitors Have Shown Remarkable Efficacy

  • / BestPractice Nordic

Gastrointestinal Cancer: 14 Years to Reach the Final Conclusion

/ Onkologi / BestPractice Nordic

Several Unsettled Questions About Breast Cancer Treatment

/ Onkologi / BestPractice Nordic

Continued Progress for the Treatment of Gynecological Cancer But No Game-Changer

/ Onkologi / BestPractice Nordic

New Treatment Possibilities Improve Future Outcomes of Lung Cancer

/ Onkologi / BestPractice Nordic

The Choice of Immunotherapy and PARP Inhibitor for Gynecological Cancer

/ Onkologi / BestPractice Nordic
Se oversigt

MEDtalks fra ESMO 2024

Gedske Daugaard

Enzalutamide plus Radium223 Treatment as First-Line for mCRPC in a Nordic Perspective

/ Gedske Daugaard
ESMO24Prostatakreft Play the Video
Silke Gillessen

PEACE-3 study: Enzalutamide and Ra-223 as First-Line Therapy for mCRPC

/ Silke Gillessen
ESMO24Prostatakreft Play the Video
Mansoor Raza Mirza

ESMO 2024: Hope and Disappointment for Ovarian Cancer Treatment

/ Mansoor Raza Mirza
ESMO24Gynekologisk kreft Play the Video
Marco Donia

Significant Updates on Neoadjuvant Treatments for Stage 3 Melanoma

/ Marco Donia
ESMO24ImmunterapiMelanom Play the Video
Andrea Botticelli

Efficacy and Safety of Targeted Therapy vs Standard of Care in Patients with Solid Tumors

/ Andrea Botticelli
ESMO24Immunterapi Play the Video

Urgent Need for More Knowledge About Quality of Life and Symptoms in Cancer Patients over 80 Years of Age

/ Elisabeth Grov Beisland
ESMO24 Play the Video

Androgen Receptor Pathway Inhibitors (ARPIs) Are Superior to Taxanes for Castrate-Resistant Metastatic Prostate Cancer

/ Henrik Grönberg
ESMO24Prostatakreft Play the Video
Ingrid Dyvik

The Role of ctDNA in Precision Oncology – New Data from the IMPRESS-Norway Study

/ Ingrid Dyvik
ESMO24 Play the Video
Jørgen Bjerggaard Jensen

ctDNA-Guided Immunotherapy Shows Promising Results to Reduce Overtreatment and Improve Outcomes for Patients with Bladder Cancer

/ Jørgen Bjerggaard Jensen
BlærekreftESMO24 Play the Video
Bjørn H. Grønberg

Høydepunkter fra ESMO 2024 om lungekreft

/ Bjørn Henning Grønberg
ESMO24Lungekreft Play the Video
Claus Andrup Kristensen

LBA35: Positive Efficacy for Eftilagimod plus Pembrolizumab in Patients with Head and Neck Squamous Cell Carcinoma

/ Claus Andrup Kristensen
ESMO24 Play the Video
Daniel Heinrich

Highlights from ESMO 2024: More Intelligent Choice of Treatment in the Future

/ Daniel Heinrich
BlærekreftESMO24NyrekreftProstatakreft Play the Video
Peter Schmid

Addition of Pembrolizumab to Standard Chemotherapy Patients with Early-Stage Triple-Negative Breast Cancer Has the Potential for a New Standard of Care

/ Peter Schmid
BrystkreftESMO24 Play the Video
Fred Saad

Darolutamide May Be an Effective Alternative Treatment Option for mHSPC

/ Fred Saad
ESMO24Prostatakreft Play the Video
Philippe Barthélémy

Updated Real-World Data Confirm the Effectiveness of Avelumab in First-Line Maintenance Treatment of Advanced Urothelial Carcinoma

/ Philippe Barthelemy
BlærekreftESMO24 Play the Video
Giuseppe Viale

Trastuzumab Deruxtecan May Become New Standard of Care After ≥1 Endocrine-Based Therapy for Patients with HER2-low and -ultralow, HR+ mBC

/ Giuseppe Viale
BrystkreftESMO24 Play the Video
Hildur Helgadottir

The Effect of Adjuvant Treatment on Overall Survival in Melanoma Stage III Patients

/ Hildur Helgadottir
ESMO24Melanom Play the Video
Nancy Lin

New Hope for Patients with Breast Cancer Including Patients with Brain Metastases

/ Nancy Lin
BrystkreftESMO24 Play the Video
Load more

ESMO 2023

Pembrolizumab + Chemotherapy: a New Standard of Carefor Triple-Negative Breast Cancer

/ Onkologi / Peter Schmid

Utvalgte ESMO 2023 Høydepunkter: Prostatakreft

/ Onkologi / Daniel Heinrich

ESMO 2023 Highlights: Practice-Changing Research in Gynecologic Cancers

/ Onkologi / Kristina Lindemann

Two New Potential Game-Changers in the Treatment of Gastroesophageal Cancer

/ Onkologi / Lene Bæksgaard

ESMO 2023: Dobling av overlevelsesraten ved innovativ behandling for metastatisk blærekreft

/ Onkologi / Daniel Heinrich

ESMO 2023 • Meet the experts

Få tilgang

KEYNOTE 522 viser forsat forbedret event-fri overlevelse for patienter med triple-negativ brystcancer

/ Ann Søegaard Knop
BrystkreftESMO23
Kristina Lindemann

Potential New Standard of Care for Locally Advanced Cervical Cancer

/ Kristina Lindemann
ESMO23Gynekologisk kreft Play the Video
Mansoor Raza Mirza

Optimizing PARP Inhibitor Therapy for Ovarian Cancer

/ Mansoor Raza Mirza
ESMO23Gynekologisk kreft Play the Video
Ellinor Haukland

Enabling Patient Empowerment Through Digital Monitoring

/ Ellinor Christin Haukland
ESMO23Pasientinvolvering Play the Video
Marco Donia

ESMO 2023 Highlights: Developments in Melanoma

/ Marco Donia
ESMO23Melanom Play the Video
Kristina Lindemann

Oppdatering fra ESMO 2023 med fokus på kreft i livmorhals-, livmor- og endometrie

/ Kristina Lindemann
ESMO23Gynekologisk kreft Play the Video
Jonathan Spicer

Perioperative Pembrolizumab Shows Significant OS in ResectableNon-Small-Cell Lung Cancer

/ Jonathan Spicer
ESMO23Lungekreft Play the Video
Henrik Grönberg

Prostate Cancer: Adaptive, Biomarker-Driven Platform Trial Shows That New Hormonal Agents Have Better Efficacy for mCRPC

/ Henrik Grönberg
ESMO23Prostatakreft Play the Video

Selected ESMO 2023 Highlights: Endometrial Cancer Treatment

/ Shannon Westin
ESMO23Gynekologisk kreft Play the Video
Mansoor Raza Mirza

New Treatment Possibilities for Patients with Recurrent or Primary Advanced Endometrial Cancer

/ Mansoor Raza Mirza
ESMO23Gynekologisk kreft Play the Video
Jaffer Ajani

Findings from the SPOTLIGHT Study Demonstrate the Power of the New Biomarker Claudin-18.2.

/ Jaffer Ajani
ESMO23Mage-tarmkreft Play the Video
Arlene Siefker-Radtke

Urothelial Cancer: One Step Forward to Understand How to Combine and Sequence Treatments Against Novel Targets

/ Arlene O. Siefker-Radtke
BlærekreftESMO23 Play the Video
Load more

MEDtalks fra ESMO 2022

Endocrine Response for Routine Decision-making on Chemotherapy use in HR+/HER2-N0-1 Early Breast Cancer

/ Onkologi / Nadia Harbeck

Current landscape in the immuno-oncology treatment of non-melanoma skin cancers

/ Dermatologi / Paolo Antonio Ascierto

Sexual health in long-term breast cancer survivors

/ Onkologi / Solveig Katrine Smedsland

ICON trial update: Ipi+Nivo combination with chemotherapy does not improve survival

/ Fastleger / Jon Amund Kyte

The clinical value of circulating tumor DNA in renal cancer

/ Onkologi / Lars Dyrskjøt Andersen

Outstanding results of ovarian cancer treatment

/ Onkologi / Clare Scott

Optimizing the front-line PARP-inhibitor treatment of ovarian cancer from a Nordic perspective

/ Onkologi / Kristina Lindemann

Efficacy of trastuzumab-deruxtecan therapy in HER2-positive breast cancer

/ Onkologi / Angelika Starzer

ESMO Highlights: Promising data for the frontline treatment of gynecologic cancer

/ Onkologi / Kristina Lindemann

ESMO Highlights: Increase awareness of supportive and palliative care for patients with cancer

/ Onkologi / Christina H. Ruhlmann

ESMO Highlights: Practical changes for treatment of lower gastrointestinal tumors

/ Onkologi / Marco Gerlinger

First-line atezolizumab treatment significantly improves overall survival in patients with NSCLC and not eligible for a platinum-containing regimen

/ Onkologi / Siow Ming Lee

Prostatakreft – høydepunkter fra ESMO 2022

/ Onkologi / Daniel Heinrich

COSMIC-313 – the first metastatic renal cell carcinoma (RCC) phase 3 trial with a doublet nivolumab plus ipilimumab

/ Onkologi / Toni K. Choueiri

Two years of ADT reduce the risk of metastases in patients undergoing post-prostatectomy radiotherapy

/ Onkologi / Chris Parker

Abstracts fra ESMO 2022

MCED blood test – a gamechanger for early cancer detection

/ BestPractice Nordic
ESMO22Kreft

Air pollution and lung cancer in never-smoking people 

/ BestPractice Nordic
ESMO22Lungekreft

Tumor-infiltrating lymphocytes improves PFS in metastatic melanoma

/ BestPractice Nordic
ESMO22Melanom

Combination of abemaciclib and trastuzumab +/- fulvestrant improved OS in women with HR+, HER2+ advanced breast cancer  

/ BestPractice Nordic
BrystkreftESMO22

A major threat to human health

/ BestPractice Nordic
ESMO22Kreft

PARP inhibitors are showing promising results in treating ovarian cancer 

/ BestPractice Nordic
ESMO22Gynekologisk kreft
Load more
Hildur Helgadottir

ESMO 2025: Superior Outcomes With Reduced NIVO+IPI Dose in Advanced Melanoma

/ Hildur Helgadottir
ESMO25Melanom Play the Video

Abstracts fra ESMO 2022

Doublet immune therapy for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy 

  • / BestPractice Nordic

ESMO 2022 –» Understanding the disease to provide better care for cancer patients»  

/ Onkologi / BestPractice Nordic
Se oversigt

ESMO 2021 • Highlights

Maintenance olaparib rechallenge in patients with ovarian carcinoma benefit outcomes

/ Eric Pujade-Lauraine
ESMO21Gynekologisk kreft Play the Video
Eric Pujade-Lauraine

PARP inhibitor olaparib shows significant improvement in PFS for patients with relapsed platinum-sensitive ovarian cancer

/ Eric Pujade-Lauraine
ESMO21Gynekologisk kreft Play the Video
Dana Chase

High-risk factors in patients with advanced ovarian cancer impact survival

/ Dana Chase
ESMO21Gynekologisk kreft Play the Video
Ma Pilar Barretina-Ginesta

First-line niraparib is associated with improvement in QA-PFS and QA-TWiST

/ Ma Pilar Barretina-Ginesta
ESMO21Gynekologisk kreft Play the Video
Roy S. Herbst

Clinical perspective of the COAST-study for unresectable Stage III NSCLC

/ Roy S. Herbst
ESMO21LungekreftNSCLC Play the Video
Roy S. Herbst

New combination with durvalumab improved ORR and PFS for unresectable Stage III NSCLC

/ Roy S. Herbst
ESMO21NSCLC Play the Video
Load more

ESMO 2021 • Highlights

Camillo Porta

New quality of life data with immune-based treatment of metastatic renal cell carcinoma

/ Camillo Porta
ESMO21Hudkreft Play the Video

Promising clinical results for heavily pretreated patients with colorectal cancer

/ Onkologi / Jared Weiss

Perspective of first line immune therapy of non-small-cell lung cancer

/ Onkologi / Ahmet Sezer

Osimertinib induction for patients with stage III metastatic EGFR NSCLC led to tumor shrinkage

/ Onkologi / Nir Peled

Potential as new standard treatment of HER2+ metastatic breast cancer

/ Onkologi / Javier Cortés

Nivolumab + chemo – a candidate for a new standard 1L treatment of advanced gastric/esophageal adenocarcinoma

/ Onkologi / Yelena Janjigian

Innhold fra ESMO 2020

Høydosert strålebehandling ved småcellet lungekreft i begrenset stadium

/ Bjørn Henning Grønberg
ESMO20Lungekreft

ESMO20: Update om lungecancer

/ Bjørn H. Grønberg
ESMO20Lungekreft Play the Video

ESMO20: Improved OS rate for metastatic, PD-L1-positive lung cancer patients

/ Julie Brahmer
ESMO20Lungekreft Play the Video

PIONeeR-studiet bringer os tættere på forståelsen af resistens mod PD-1/L1 inhibitorer

ESMO20Lungekreft

Lovende effekt på hjernemetastaser placerer osimertinib som adjuverende behandling af EGFR-positiv ikke-småcellet lungecancer

ESMO20Lungekreft

The AKT inhibitor ipatasertib in combination with abiraterone shows promising results in castration-resistant prostate cancer

BrystkreftESMO20

CDK 4/6-hæmmeren abemacitib i tidlig brystkræft har potentialet til at ændre praksis

BrystkreftESMO20

KEYNOTE 590 – Immunterapi kan blive ny førstelinjebehandling ved avanceret esophaguscancer

ESMO20Kreft
Mere

Back to top